{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jongkhajornpong P"],"funding":["Medical Council of Thailand","Faculty of Medicine, Ramathibodi Hospital, Mahidol University"],"pagination":["e001857"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11474780"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Objective
The 0bjective is to compare treatment effects between undiluted autologous platelet-rich plasma (APRP) and autologous serum (AS) in patients with moderate-to-severe dry eye disease (DED).Methods and analysis
A single-centre, randomised, double-masked, non-inferiority clinical trial was conducted. 96 adult DED patients with an Ocular Surface Disease Index (OSDI) Score of ≥23 and/or Oxford staining grade of ≥2 were randomised to receive either 100% APRP (n=48) or 100% AS (n=48) for 4 weeks. Primary outcomes included OSDI Score and ocular surface staining measured by Oxford grading scale at 4 weeks. Secondary outcomes included fluorescein tear break-up time, Schirmer's test, meibum quality and expressibility, and adverse events. The 95% CI for the mean difference in "],"journal":["BMJ open ophthalmology"],"pubmed_title":["Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial."],"pmcid":["PMC11474780"],"funding_grant_id":["64004","2021"],"pubmed_authors":["Rattanasiri S","Thakkinstian A","Jongkhajornpong P","Attia J","Lekhanont K","McKay G","Numthavaj P"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial.","description":"Objective
The 0bjective is to compare treatment effects between undiluted autologous platelet-rich plasma (APRP) and autologous serum (AS) in patients with moderate-to-severe dry eye disease (DED).Methods and analysis
A single-centre, randomised, double-masked, non-inferiority clinical trial was conducted. 96 adult DED patients with an Ocular Surface Disease Index (OSDI) Score of ≥23 and/or Oxford staining grade of ≥2 were randomised to receive either 100% APRP (n=48) or 100% AS (n=48) for 4 weeks. Primary outcomes included OSDI Score and ocular surface staining measured by Oxford grading scale at 4 weeks. Secondary outcomes included fluorescein tear break-up time, Schirmer's test, meibum quality and expressibility, and adverse events. The 95% CI for the mean difference in ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T03:58:07.472Z","creation":"2025-04-04T11:05:39.07Z"},"accession":"S-EPMC11474780","cross_references":{"pubmed":["39384222"],"doi":["10.1136/bmjophth-2024-001857"]}}